{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:28:35Z","timestamp":1787016515700,"version":"build-2736575974"},"reference-count":39,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T00:00:00Z","timestamp":1681776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T00:00:00Z","timestamp":1681776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2023,4,18]]},"abstract":"<jats:p>\n                    Omadacycline, a novel aminomethylcycline with\n                    <jats:italic>in vitro<\/jats:italic>\n                    activity against Gram-positive and -negative organisms, including\n                    <jats:named-content content-type=\"genus-species\">Streptococcus pneumoniae<\/jats:named-content>\n                    and\n                    <jats:named-content content-type=\"genus-species\">Haemophilus influenzae<\/jats:named-content>\n                    , is approved in the United States to treat patients with community-acquired bacterial pneumonia (CABP). Using nonclinical pharmacokinetic-pharmacodynamic (PK-PD) targets for efficacy and\n                    <jats:italic>in vitro<\/jats:italic>\n                    surveillance data for omadacycline against\n                    <jats:named-content content-type=\"genus-species\">S. pneumoniae<\/jats:named-content>\n                    and\n                    <jats:named-content content-type=\"genus-species\">H. influenzae<\/jats:named-content>\n                    , and a population pharmacokinetic model, PK-PD target attainment analyses were undertaken using total-drug epithelial lining fluid (ELF) and free-drug plasma exposures to evaluate omadacycline 100\u2009mg intravenously (i.v.) every 12\u2009h or 200\u2009mg i.v. every 24\u2009h (q24h) on day 1, followed by 100\u2009mg i.v. q24h on day 2 and 300\u2009mg orally q24h on days 3 to 5 for patients with CABP.\n                  <\/jats:p>","DOI":"10.1128\/aac.02213-21","type":"journal-article","created":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T10:04:14Z","timestamp":1679479454000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":15,"title":["Pharmacokinetic-Pharmacodynamic Target Attainment Analyses Evaluating Omadacycline Dosing Regimens for the Treatment of Patients with Community-Acquired Bacterial Pneumonia Arising from Streptococcus pneumoniae and Haemophilus influenzae"],"prefix":"10.1128","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4891-6467","authenticated-orcid":true,"given":"Sujata M.","family":"Bhavnani","sequence":"first","affiliation":[{"name":"Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey P.","family":"Hammel","sequence":"additional","affiliation":[{"name":"Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Lakota","sequence":"additional","affiliation":[{"name":"Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3468-3343","authenticated-orcid":true,"given":"Michael","family":"Trang","sequence":"additional","affiliation":[{"name":"Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin C.","family":"Bader","sequence":"additional","affiliation":[{"name":"Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catharine C.","family":"Bulik","sequence":"additional","affiliation":[{"name":"Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6527-1475","authenticated-orcid":true,"given":"Brian D.","family":"VanScoy","sequence":"additional","affiliation":[{"name":"Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3172-0847","authenticated-orcid":true,"given":"Christopher M.","family":"Rubino","sequence":"additional","affiliation":[{"name":"Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9769-9019","authenticated-orcid":true,"given":"Michael D.","family":"Huband","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Friedrich","sequence":"additional","affiliation":[{"name":"Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith N.","family":"Steenbergen","sequence":"additional","affiliation":[{"name":"Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2230-1125","authenticated-orcid":true,"given":"Paul G.","family":"Ambrose","sequence":"additional","affiliation":[{"name":"Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2009.129502"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61682-2"},{"key":"e_1_3_3_4_2","first-page":"1","article-title":"Deaths: leading causes for 2015","volume":"66","author":"Heron M","year":"2017","unstructured":"Heron M. 2017. Deaths: leading causes for 2015. Natl Vital Stat Rep 66:1\u201376.","journal-title":"Natl Vital Stat Rep"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.2010.03.2130"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500245"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ1214"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17122120"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02327-17"},{"key":"e_1_3_3_10_2","unstructured":"Dubois J Dubois M Steenbergen JN. 2018. In vitro activity of omadacycline against resistant Streptococcus pneumoniae and Haemophilus influenzae abstr 1153. Abstr 28th Eur Cong Clin Microbiol Infect Dis Madrid Spain."},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02488-19"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2020.115054"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2021.09.011"},{"key":"e_1_3_3_14_2","unstructured":"Paratek Pharmaceuticals Inc. May 2021. NUZYRA (omadacycline)\u00ae package insert. Paratek Pharmaceuticals Inc Boston MA."},{"key":"e_1_3_3_15_2","unstructured":"United States Department of Health and Human Services Food and Drug Administration. June 2020. Guidance for industry. Community-acquired bacterial pneumonia: developing drugs for treatment. https:\/\/www.fda.gov\/media\/75149\/download. Accessed 2 February 2022."},{"key":"e_1_3_3_16_2","unstructured":"European Medicines Agency Committee for Medicinal Products for Human Use. 21 July 2016. Guideline on the use of pharmacokinetics and pharmacodynamics in the development of antibacterial medicinal products. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-use-pharmacokinetics-pharmacodynamics-development-antimicrobial-medicinal-products_en.pdf. Accessed 2 February 2022."},{"key":"e_1_3_3_17_2","unstructured":"Noel GJ Draper M Hait H Tanaka SK. 2012. Safety and efficacy of PTK0796 (omadacycline) as treatment of complicated skin and soft tissue infection (cSSTI) poster P694. Abstr 22nd Eur Cong Clin Microbiol Infect Dis London United Kingdom."},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1800201"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1800170"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30275-0"},{"key":"e_1_3_3_21_2","unstructured":"Van Wart SA Manley A Bhavnani SM Tanaka K Loh E Rubino CM Tzanis E Ambrose PG. 2016. Population pharmacokinetics of omadacycline following intravenous or oral administration to phase 1 subjects poster P1320. Abstr 26th Eur Congr Clin Microbiol Infect Dis Amsterdam Netherlands."},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02263-19"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02368-16"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02265-19"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.4.943-949.2000"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.3109\/9781420017137.013"},{"key":"e_1_3_3_27_2","unstructured":"VanScoy BD Lakota EA Adams J Bhavnani SM Newman J Ambrose PG. 2017. Pharmacokinetics-pharmacodynamics of efficacy for eravacycline against Escherichia coli in an in vitro infection model poster Sunday-189. Microbe 2017 New Orleans LA 1 to 5 June 2017."},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00250-17"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1086\/653057"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2017.09.009"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2017.09.019"},{"key":"e_1_3_3_32_2","unstructured":"Bulik CC Bhavnani SM Hammel J Forrest A Dudley MN Ellis-Grosse EJ Drusano GL Ambrose PG. 2013. Relationship between regulatory approval and pharmacokinetic-pharmacodynamic target attainment: focus on community- and hospital-acquired pneumonia abstr A-295. 53rd Intersci Conf Antimicrob Agents Chemother Denver CO."},{"key":"e_1_3_3_33_2","unstructured":"Bhavnani SM Hammel JP Onufrak NJ Wicha WW Paukner S Sader HS Rubino CM Schranz J Gelone SP Ambrose PG. 2019. Pharmacokinetic-pharmacodynamic (PK-PD) target attainment analyses to support lefamulin dose justification and susceptibility breakpoint determinations for patients with community-acquired bacterial pneumonia (CABP) abstr P1946. 29th Eur Congr Clin Microbiol Infect Dis Amsterdam Netherlands 13 to 16 April 2019."},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2017.06.002"},{"key":"e_1_3_3_35_2","unstructured":"United States Department of Health and Human Services Food and Drug Administration. 28 August 2020. Omadacycline injection and oral products. https:\/\/www.fda.gov\/drugs\/development-resources\/omadacycline-injection-and-oral-products. Accessed 22 February 2022."},{"key":"e_1_3_3_36_2","doi-asserted-by":"crossref","unstructured":"Overcash JS Bhiwandi P Garrity-Ryan L Steenbergen J Bai S Chitra S Manley A Tzanis E. 2019. Pharmacokinetics safety and clinical outcomes of omadacycline in women with cystitis: results from a phase 1b study. Antimicrob Agents Chemother 63:e02083-18. 10.1128\/AAC.02083-18. e02083-18","DOI":"10.1128\/AAC.02083-18"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01135-17"},{"key":"e_1_3_3_38_2","unstructured":"Baron KT Hindmarsh AC Petzold LR Gillespie B Margossian C. Metrum research group LLC (NA). mrgsolve: simulation from ODE-based population PK\/PD and systems pharmacology models. R package version 0.7.5."},{"key":"e_1_3_3_39_2","volume-title":"R: a language and environment for statistical computing.","author":"R Development Core Team","year":"2016","unstructured":"R Development Core Team. 2016. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria."},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01784-16"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.02213-21","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.02213-21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T09:07:22Z","timestamp":1681808842000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.02213-21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,18]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4,18]]}},"alternative-id":["10.1128\/aac.02213-21"],"URL":"https:\/\/doi.org\/10.1128\/aac.02213-21","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,18]]},"assertion":[{"value":"2022-02-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02213-21"}}